1. S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab.

    Molecular Cancer Therapeutics 12(9):1749 (2013) PMID 23804704

    Aberrant activity of the receptor tyrosine kinases MET, AXL, and FGFR1/2/3 has been associated with tumor progression in a wide variety of human malignancies, notably in instances of primary or acquired resistance to existing or emerging anticancer therapies. This study describes the preclinical...
  2. [Contribution to new therapeutics against colorectal cancer: the CReMEC initiative].

    médecine/sciences 29(3):239 (2013) PMID 23544371

  3. Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer.

    Clinical Cancer Research 18(19):5314 (2012) PMID 22825584

    Patient-derived xenograft models are considered to represent the heterogeneity of human cancers and advanced preclinical models. Our consortium joins efforts to extensively develop and characterize a new collection of patient-derived colorectal cancer (CRC) models. From the 85 unsupervised surgi...
  4. Specific oncogenic activity of the Src-family tyrosine kinase c-Yes in colon carcinoma cells.

    PLoS ONE 6(2):e17237 (2011) PMID 21390316 PMCID PMC3044743

    c-Yes, a member of the Src tyrosine kinase family, is found highly activated in colon carcinoma but its importance relative to c-Src has remained unclear. Here we show that, in HT29 colon carcinoma cells, silencing of c-Yes, but not of c-Src, selectively leads to an increase of cell clustering a...